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Abstract: Effective tight glycemic control (TGC) can improve outcomes in intensive care unit (ICU) 
patients, but is difficult to achieve consistently. Glycemic level and variability, particularly early in a 
patient’s stay, are a function of variability in insulin sensitivity/resistance resulting from the level and 
evolution of stress response, and are independently associated with mortality. This study examines the 
daily evolution of variability of insulin sensitivity in ICU patients using patient data (N = 394 patients, 
54019 hours) from the SPRINT TGC study. Model-based insulin sensitivity (SI) was identified each hour 
and hour-to-hour percent changes in SI were assessed for Days 1-3 individually and Day 4 Onward, as 
well as over all days. Cumulative distribution functions (CDFs), median values, and inter-quartile points 
(25th and 75th percentiles) are used to assess differences between groups and their evolution over time. 
Compared to the overall (all days) distributions, ICU patients are more variable on Days 1 and 2 (p < 
0.0001), and less variable on Days 4 Onward (p < 0.0001). Day 3 is similar to the overall cohort (p = 0.74). 
Absolute values of SI start lower and rise for Days 1 and 2, compared to the overall cohort  (all days), (p < 
0.0001), are similar on Day 3 (p = .72) and are higher on Days 4 Onward (p < 0.0001). ICU patients have 
lower insulin sensitivity (greater insulin resistance) and it is more variable on Days 1 and 2, compared to 
an overall cohort on all days. This is the first such model-based analysis of its kind. Greater variability 
with lower SI early in a patient’s stay greatly increases the difficulty in achieving and safely maintaining 
glycemic control, reducing potential positive outcomes. Clinically, the results imply that TGC patients will 
require greater measurement frequency, reduced reliance on insulin, and more explicit specification of 
carbohydrate nutrition in Days 1-3 to safely minimise glycemic variability for best outcome. 
 
1. INTRODUCTION 
There are strong physiological links between maintaining 
normal glycemic levels and variability, and improved 
immune response to infection (Weekers et al., 2003) as well 
as reductions in organ failure (Van den Berghe et al., 2001). 
Thus, tight glycemic control (TGC) by intensive insulin 
therapy (IIT) has successfully reduced organ failure and/or 
mortality in some prior studies (Van den Berghe et al., 2001, 
Krinsley, 2004, Chase et al., 2008). However, safely 
achieving improved outcomes with TGC has been difficult 
(Finfer et al., 2009, Preiser et al., 2009) due largely to 
significant increases in hypoglycemia and glycemic 
variability in TGC cohorts. 
 
Glycemic level, range and variability are associated with 
increased organ failure and risk of death (Egi et al., 2006). 
Early hypoglycemia and increased glycemic range on Day 1 
of a patient’s stay, have also shown an increased risk of death 
(Bagshaw et al., 2009). Finally, hypoglycemia itself has been 
linked to poor outcome (Egi et al., 2006). All these outcomes 
result from the variability in these patients response to insulin 
or their variability in insulin sensitivity. They are exacerbated 
by TGC protocols that use larger insulin doses and/or 
infrequent sampling (Wilson et al., 2007), both of which 
allow outcome glycemia to vary more greatly. As a result 
there have been calls to increase target glycemic levels to 
avoid hypoglycemia (Cerra et al., 1997). 
 
This study examines the evolution and variability of insulin 
sensitivity (1/insulin resistance) over the first days of an ICU 
patient’s stay. It implicitly hypothesizes that it is increased 
variability in insulin sensitivity early in a patient’s stay that 
makes achieving safe, effective TGC more difficult, 
increasing the risk of hypoglycemia and glycemic variability, 
and thus of poor outcomes. 
2. METHODS 
2.1 Patients and Data: 
This study uses data from 394 patients treated on SPRINT 
(August 2005 – May 2007) for whom all APACHE and other 
data was available (Chase et al., 2008). Their overall 
glycemic data are shown combined and independently in 
Table 1, including summary glycemic control metrics. The 
Upper South Regional Ethics Committee (NZ) granted ethics 
approval for the audit, analysis and publication of this data. 
 
     
Table 1:  Patient data summary 
 SPRINT 
Total patients 394 
Age (years) 65 [50 – 74] 
% Male 62.9% 
Diabetic history 67 (17.0%) 
  
APACHE II score 18 [14 – 24] 
APACHE II risk of death 25.6% 
[13.1% - 49.4%] 
  
ICU LoS [median, IQR] (days) 4.0 [1.7 – 10.4] 
  
Median BG (SD) (mmol/L) 6.0 (1.5) 
% BG in 4.4-6.1 mmol/L 53.9% 
% BG in 4.0-7.0 mmol/L  79.0% 
% BG < 2.2 mmol/L 0.1% 
  
Patients on Day 1 394 
Patients on Day 2 264 
Patients on Day 3 201 
Patients on Day 4 181 
2.2 Metabolic System Model: 
A clinically validated computer model of the metabolic 
system (Chase et al., 2007) is used to identify patient-
specific, time-varying (hourly) insulin sensitivity (SI) every 
hour:  
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Where G(t) [mmol/L] is plasma glucose I(t) [mmol/L] is 
plasma insulin, uex(t) [mU/min] is exogenous insulin input, 
basal endogenous insulin secretion is IB [mU/L/min], with kI 
representing suppression of basal secretion by exogenous 
insulin. Interstitial insulin is Q(t) [mU/L], with k [1/min] 
accounting for losses and transport. Body and brain weight 
are denoted by mbody [kg] and mbrain [kg]. Endogenous glucose 
clearance is pG [1/min] and time-varying insulin sensitivity is 
SI or (formally) SI(t) in Equation (1) [L/(mU.min)]. Finally, 
VI,frac [L/kg] is the insulin distribution volume per kg body 
weight and n [1/min] is the transport rate of insulin from 
plasma. Total plasma glucose input is P(t) [mmol/min], 
endogenous glucose production is PEND [mmol/kg/min] and 
VG,frac [L/kg] represents the glucose distribution volume per 
kg body weight. CNS [mmol/kg/min] captures non-insulin 
mediated glucose uptake by the central nervous system. 
Michaelis-Menten functions model saturation, with αI 
[L/mU] for the saturation of plasma insulin disappearance, 
and αG [L/mU] for insulin-dependent glucose clearance 
saturation. 
 
These parameters and their clinically validated values are 
well documented in the literature (Lin et al., 2008), and have 
been used in several clinical TGC studies and to create 
SPRINT. The model has also shown good correlation to gold 
standard research assessments (Lotz et al., 2006) in clinical 
metabolic research studies. Hence, the insulin sensitivity 
metric (SI) is a well validated metric that captures the whole 
body metabolic tradeoff of insulin and glucose, thus 
reflecting the hyperglycemic counter regulatory stress 
response and its variability that is seen in the critically ill. 
2.3 Insulin Sensitivity (SI) and Variability: 
The value of SI can be identified every hour using clinical 
data for blood glucose concentration, insulin administered 
and the carbohydrate nutrition administered from all sources 
(Hann et al., 2005). Its hourly variation can be obtained as the 
difference from one hour to the next, so that at hour (n+1): 
∆SI,n+1 = SIn+1 – SIn; or as a percentage change from the prior 
value: %∆SI,n+1 = (SIn+1 – SIn)/SIn+1*100, normalising values 
to a patient-specific level.  Mathematically, this definition of 
%∆SI,n+1 limits positive changes (increase in SI from hour n 
to hour n+1) to 100% while drops in SI are not capped. These 
values for ∆SI,n+1 and %∆SI,n+1 are aggregated for each day of 
ICU stay. 
2.4 Analysis and Statistics: 
SI and its percent variation are plotted as cumulative 
distribution functions (CDFs) for Days 1, 2 and 3 of ICU 
stay. Day 4 Onward values are grouped. Variability at 
different levels of SI is normalised by presenting it as a 
percentage change instead of an absolute value.  
 
Absolute values of SI are compared using the non-parametric 
Mann-Whitney test as distributions are skewed. Variability 
across days is assessed by comparing the number of %∆SI,n+1 
values within ±15% to those outside this range, thus 
comparing the central portions of the CDF to those outlying 
portions of either positive or negative change. These values 
are compared using a Chi Squared test on a 2x2 contingency 
table. The ±15% range was chosen as a level below which 
clinical assay errors and other clinically insignificant 
variations dominate the model-based metric’s variability. It 
thus separates clinically insignificant (within) and clinically 
significant (outside) variations. A value of p < 0.005 is 
considered significant given the large number of data points. 
 
3. RESULTS 
Figure 1 shows the CDFs for SI on Days 1-3, 4 Onwards and 
for the total overall cohort (all days). Table 2 shows the 
median and inter-quartile ranges (IQR) for SI on each day. 
Each of Days 1-3 and Day 4 Onwards are different (p < 
0.0001), and Days 1-2 and Days 4 Onward are different from 
the overall total cohort (all days, p < 0.0001). Day 3 and the 
overall cohort, as seen in the graph, are similar (p = 0.72). It 
is clear that median and overall SI increase daily, with Days 4 
Onward surpassing the total overall cohort (all days) results. 
     
 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
x 10-3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
SI (L/mU/min)
C
um
ul
at
iv
e 
D
en
si
ty
 F
un
ct
io
n
 
 
All Days (Overall)
Day 1
Day 2
Day 3
Days 4 Onward
 
Figure 1: CDFs of SI for Days 1-3, Day 4 Onwards and the 
total overall cohort (all days). 
 
Table 2: SI values (median [IQR]) for each day(s) analysed, 
where SI has units of (L/mU/min * 10-3). 
Day SI: median [IQR] 
1 0.169  [0.095,  0.270] 
2 0.224  [0.143,  0.339] 
3 0.242  [0.162,  0.336] 
4 Onward 0.261  [0.182,  0.354] 
Total (all days) 0.242  [0.159,  0.341] 
 
For clarity, Figure 2 shows the CDFs of percent change SI 
variability for the total overall cohort (all days) and for Days 
1 and 2. The figure is repeated, but for Days 3 and 4 Onward 
in Figure 3. It is clear that variability decreases on all days 
from Days 1-3 and then Days 4 Onward. All curves for each 
day noted are different (p < 0.0001) from each other. Days 1-
2 and Days 4 Onward are different from the total overall (all 
days) with (p < 0.0001).  
 
In particular, Days 4 Onward have less variability, and Days 
1 and 2 greater variability, as is evident in the figures. Day 3 
and the total overall cohort (all days) have similar variability 
(p = 0.74). The median and IQR values for each curve are 
shown in Table 3. 
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Figure 2: CDFs of SI variability for Days 1 and 2 versus the 
overall cohort (all days). 
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Figure 3: CDFs of SI variability for Days 3 and 4 Onwards 
versus the overall cohort (all days). 
 
Table 3: %∆SI values (median [IQR]) for each day(s) 
analysed in (%). 
Day ΔSI: median [IQR] 
1  3.6    [-22.0, 25.3] 
2  1.5    [-14.5, 15.9] 
3  1.2    [-12.2, 13.5] 
4 Onward -0.15  [-9.3, 10.5] 
Total (all days) <0.01   [-11.2, 13.1] 
 
Similar to the trends for SI, amount of changes greater than 
±15% decrease for each day that passes. Days 1-2 are more 
variable than the total overall cohort (p < 0.0001), Day 3 is 
less different (p = 0.74), and Days 4 Onward are less variable 
(p < 0.0001). These results are also evident in the curves of 
Figures 2-3, and data of Table 3. 
 
4. DISCUSSION 
Several studies have examined inflammation and stress 
response, and their metabolic outcome as stress 
hyperglycemia in critically ill cohorts (e.g. (Marik and 
Raghavan, 2004)). With respect to TGC, the anti-
inflammatory role of insulin has also been examined. 
However, to the authors’ knowledge, none have made 
specific comparisons of the strength, time course or 
behaviour of the stress response across a broad cohort. This 
study effectively compares the evolution and strength of this 
stress response using its metabolic impact (assessed by SI 
here) as a surrogate marker. 
 
Figures 1-3 and Tables 2-3 clearly show four main outcomes: 
1) ICU patients have a lower insulin sensitivity (greater 
resistance) in the first 1-2 days compared to analyses that 
have in past looked only at the whole cohort and all days 
(Langouche et al., 2007, Lin et al., 2008); 2) ICU patients are 
more dynamically variable in their SI (more variable insulin 
resistance) than the overall cohort (over all days) in the first 
1-2 days and similar on Day 3; 3) SI and its variability are 
reduced, compared to the overall cohort (all days) behaviours 
for Days 4 Onward; and 4) SI rises and variability decreases 
over each day of stay, and the differences between days are 
significant both statistically and clinically. 
 
     
In the original SPRINT study (Chase et al., 2008), glycemic 
control metrics, as seen in Table 1, were not a significant 
factor in differentiating survivors and non-survivors within 
the SPRINT cohort. Thus, given the large number of hours 
shown and significant variability, the quality of glycemic 
control was not a factor in these results.  
 
It should also be noted that the trends for increasing SI over 
time matches results reported in other studies (Langouche et 
al., 2007). Similarly, TGC-based mortality improvements 
were evident in SPRINT after 3 days of ICU stay, at which 
point the overall cohort average is equal to the daily 
behaviour of SI and its variability. Hence, Day 3 represents a 
crossover point in patient behaviour versus its overall long 
term total behaviour. 
 
More specifically, the insulin sensitivity variability observed 
may be the primary reason for the outcome variability and 
hypoglycemia seen in many other TGC studies. In particular, 
many TGC protocols administer insulin to relatively high 
levels in the face of the initial high insulin resistance (low SI) 
seen here, including doses of up to 15 U/hour for a blood 
glucose concentration of 8.0-9.0 mmol/L, as reported in 
(Wilson et al., 2007). This insulin sensitivity variability, 
combined with relatively high(er) insulin doses, will result in 
greater glycemic variability and thus increased risk of 
hypoglycemia for many protocols, especially in the first days. 
More insulin sensitive cohorts (higher SI, as in (Suhaimi et 
al., 2010)) will further multiply this variability if insulin 
dosing isn’t implicitly or explicitly titrated to SI. The direct 
outcome is poor control, increased hypoglycemia and poor 
outcome, matching recent reports (Griesdale et al., 2009). 
 
The strong inflammatory stress and immune responses that 
occur after insult or the onset of all forms of critical illness 
are well studied (Marik and Raghavan, 2004). Their general 
persistence and/or decrease over time and treatment has also 
been studied in some cases (Quaniers et al., 2006), including 
the impact of insulin (Krogh-Madsen et al., 2004). Changes 
in whole body glucose uptake and insulin sensitivity due to 
the impact of counter regulatory hormones and pro-
inflammatory cytokines, captured here by SI, are complex 
and.may be a (currently unknown) function of the severity of 
illness, stage or time of the disease or insult, evolution of 
disease state, as well as a function of the treatment with 
insulin, whether normo-glycemia is maintained, or other anti-
inflammatory effects, and/or increased non-insulin mediated 
glucose uptake. The results presented capture this behaviour 
with the overall model-based SI metric, which indicates the 
impact of this whole body stress response on outcome 
glycemia, providing a source of overall validation for the 
results found.  
 
While the patho-physiology of these stress responses is well 
understood, their specific day-to-day dynamic evolution, and 
thus the variability observed here, is not as well understood. 
In many forms of critical illness, inflammatory cytokines and 
counter regulatory hormones have been observed to rise 
(Quaniers et al., 2006). However, whether these rises persist 
or decrease depends on the study and the treatment, 
particularly with respect to elements that reduce 
inflammation – notably the use of insulin and the ability to 
maintain normoglycemia (Weekers et al., 2003). Further, the 
potentially large and rapid changes seen may also be due to 
the high secretion rates due to stress, combined with 
relatively short half lives in plasma, of inflammatory 
cytokines and counter-regulatory hormones in these cohorts.  
 
One overall potential limitation in the generality of this study 
is the level of tight control provided by SPRINT. Lower 
glycemic levels reduce physiological stress and inflammatory 
markers (e.g. (Weekers et al., 2003)). Thus, the control 
provided by SPRINT, which was consistent across all 
patients, may have resulted in the decrease in variability and 
general increase in SI over Days 1-4. It should be noted that 
this general increase in insulin sensitivity over time and as 
patients improve matches results seen in other studies 
(Langouche et al., 2007). However, and in contrast, a less 
well controlled cohort might see increased variability and/or 
reduced SI for longer periods of time. This issue would 
require data from another study for confirmation, linking 
variability to glycemic level (and thus inflammatory status), 
and thus remains an open issue. 
 
It should also be noted that the number of patients decreases 
over time, as expected. However, the number of hours on any 
day is never less than 1700. Thus, there are enough data 
points and data density to ensure a consistent result that is 
unaffected by outliers. All patients were grouped in this 
analysis, regardless of diagnostic code. There may exist 
variability across diagnoses, which may be further elucidated 
by analysing sub-sets of larger cohorts of patient data. 
 
With respect to the metric chosen, the SI parameter is a 
model-based measure of overall metabolic balance and whole 
body insulin sensitivity. It is highly correlated to the gold 
standard euglycemic clamp (R = 0.98) (Lotz et al., 2006), and 
has been extensively used and validated in a wide range of 
insulin sensitivity tests . It has also been shown to capture 
overall patient status in its use as part of a sepsis biomarker 
(Blakemore et al., 2008), and in predictive, real-time ICU 
glycemic control studies. Hence, it is a well validated 
measure that captures the fundamental metabolic behaviours 
important in this study. 
 
Prior work by the authors group had shown that variability in 
metabolic response, using the same SI parameter, could be 
quite large (Lin et al., 2008). However, these studies had not 
considered differences over time. Advanced glycemic control 
protocols can take advantage of this knowledge to improve 
safety by accounting for the variability in SI and thus the 
variability outcome glycemia in response to an insulin 
intervention (Le Compte et al., 2009, Lin et al., 2008). 
 
Clinically, these results have significant implications for the 
implementation of TGC. Enhanced variability in SI leads 
potentially to enhanced variability in the blood glucose level 
resulting from a given insulin intervention (Lin et al., 2008). 
In addition, the variability shown in Figures 2-3 is hourly, 
     
where the greater variability shown implies a greater 
variability in blood glucose for longer intervals between 
measurements (Lonergan et al., 2006). These effects are 
multiplied by the overall insulin sensitivity of the cohort, 
where, for example, the Glucontrol cohort at the Liege centre 
were approximately 1.5-2.0x more sensitive than the SPRINT 
cohort (Suhaimi et al., 2010). The overall outcome is greater 
glycemic variability and a greater risk of both hyperglycemia 
and hypoglycemia. Thus, since glycemic variability and 
hypoglycemia are independent risk factors for the critically 
ill, it is important to manage these dynamics when 
implementing TGC. 
 
More specifically, in implementing TGC, these results 
indicate that protocols should seek to minimise or reduce 
excessive insulin usage in the first 1-3 days while 
maintaining control to a given target. Given a high level of 
insulin resistance and the saturation of insulin action (Natali 
et al., 2000), the implication is that the level of carbohydrate 
administration and thus nutrition inputs, formulas and 
practice should be explicitly considered. In particular, 
SPRINT explicitly controlled nutritional inputs and used a 
low-carbohydrate nutritional formula to ensure better and 
more robust control. Thus, excessive nutritional regimes 
(high or low) might be avoided in consideration of an explicit 
choice that also helps manage the metabolic dynamics 
observed in this study, as supported by other studies 
(Krishnan et al., 2003). 
 
Finally, these findings have clinical implications for 
advocates of early and/or high nutritional therapies (Martin et 
al., 2004). The potential benefit of early enteral or parenteral 
feeding may be lost if the variability it induces through 
requiring higher insulin doses to maintain normal or near-
normal glycemia result in excessive glycemic variability and 
range, and/or hypoglycemia. Similarly, the benefits of early 
nutritional support may be difficult to delineate if glycemic 
control is not similar, resulting in ambiguous clinical and 
research outcomes (Doig et al., 2008). 
 
5. CONCLUSIONS 
This study presents results from a unique analysis that 
evaluates the metabolic dynamics of patients over time. Three 
main conclusions are drawn from this analysis. It is the first 
such study of its kind and shows the ability of clinically 
validated physiological models to quantitatively capture 
clinically important trends that might otherwise be missed, 
but have significant impact on the delivery of care and thus 
patient outcome.  
 
First, SI rises over time, matching reports from other studies 
that looked only at selected days. This analysis clearly shows 
that SI is much lower (resistance is much higher) on Days 1-2 
compared to the overall cohort, and keeps improving up 
through Day 3-4. Second, the same trends hold for insulin 
sensitivity variability, with variability decreasing over time. 
Hence, insulin sensitivity variability may be the primary 
reason for the outcome variability and hypoglycemia seen in 
many other TGC studies. In particular, those protocols that 
utilise higher insulin doses and/or measure infrequently will 
be more likely to see greater glycemic variability and 
hypoglycemia in the first days, which is linked to poor 
outcome. Cohorts and patients with higher insulin sensitivity 
will multiply these effects. Third, managing this variability 
will require minimising relative insulin use in the first 2-3 
days of care, as well as more explicit consideration of 
carbohydrate and overall nutritional inputs if tight glycemic 
control is to be safely achieved and maintained.  
 
Overall, these results imply that TGC protocols should be 
able to accurately estimate insulin sensitivity as part of their 
operation, providing a strong impetus to support model-based 
control methods as a best-practice approach. 
 
These main conclusions remain to be prospectively tested. 
However, this unique data driven analysis highlights several 
important outcomes with respect to the analysis and 
implementation of TGC protocols, and should inform future 
protocol designs and studies.  
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